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eplerenone decreased cardiovascular mortality and deaths from
any cause by 15% (p = 0.008) in patients with acute myocardial
infarction complicated by left ventricular dysfunction and heart
failure. An economic evaluation was performed to asses the
cost-effectiveness of epleronone vs. placebo through patient life-
time in the Spanish setting. METHODS: The cost-effectiveness of
eplerenone in cost per Life-Year (LYG) and Quality-Adjusted-
Life-Years (QALY) gained compared to placebo was estimated.
Efﬁcacy data from EPHESUS study during the 16 month
follow-up period were used. Survival data beyond trial period
were estimated from the Framingham Heart Study Registry. The
study was carried out from societal perspective; therefore, only
direct medical costs where included. Drug acquisition costs were
priced at AWP (average wholesale price), €2007. Costs were
obtained from Spanish databases. Costs and effects were dis-
counted 3% annually. Sensitivity analyses were carried out based
on alternative life-years gained estimates from the Saskatchewan
Health database and Worcester Heart Attack Registry Data,
(0.0636 and 0.1337 respectively). RESULTS: The number of
LYG with eplerenone was 0.1014 based on Framingham. Cost
was €1016.90 higher over the trial period in the eplerenone arm
because of drug cost (€1,164.07). The Framingham incremental
cost-effectiveness ratio (ICER) of eplerenone compared to
placebo was 10,030€ per LYG and 15,047€ per QALY gained.
Sensitivity analyses showed eplerenone was efﬁcient under
alternative life expectancy estimates: €15,99€ per LYG with
Saskatchewan and €7,60€ per LYG with Worcester. CONCLU-
SIONS: Selective aldosterone blockade with eplerenone is a cost-
effective strategy in post-AMI patients with heart failure in Spain.
In addition to standard therapy, eplerenone prevents events,
saves hospitalization resources and improves survival among
these patients.
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OBJECTIVES: Clopidogrel has shown to be cost-effective to
prevent ischemic events in non-ST segment elevation acute coro-
nary syndromes (NSTEACS). This study is intended to assess
the cost-effectiveness of clopidogrel in long-term treatment of
ST-segment elevation myocardial infarction (STEMI) in Spain.
METHODS: A combined decision tree and Markov model was
constructed. Efﬁcacy data was obtained from CLARITY and
COMMIT trials for the ﬁrst month, and the “CAPRIE-like”
cohort of CHARISMA trial (months 2–12). The risks of death,
myocardial infarction, and stroke in an untreated population and
long-term survival after all events were derived from the Swedish
Hospital Discharge and Cause of Death register. A payer perspec-
tive was chosen for the analysis, using local costs. Effectiveness
was measured as the number of life-years gained (LYG) with
clopidogrel treatment. Costs and effects were discounted at 3%.
RESULTS: The difference in stroke rates was more pronounced
in CLARITY (0.9% vs. 1.7% and 0.55% vs. 0.62% in the
CLARITY and COMMIT respectively) and thus facilitates
important cost savings. In two patient cohorts with the same
characteristics and event rates as in the CLARITY and COMMIT
population, treatment with clopidogrel for up to 1 year opposed
to treatment with ASA resulted in ICERs (€/LYG)of: in
CLARITY cohort €397 and in COMMIT cohort €2927. CON-
CLUSIONS: Treatment of STEMI patients with clopidogrel
appeared to be cost-effective in long-term with predicted ICERs
below generally accepted threshold value of €30,000/LYG.
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OBJECTIVES: Abdominal Aortic Aneurysm (AAA) is deﬁned as
a localized dilatation of aortic vessel. It’s predominantly asymp-
tomatic, but represents a chronic degenerative condition associ-
ated with life-threatening risk of rupture. The early diagnosis of
AAA, i.e. before its ruptures, is therefore important and ultra-
sound examination is a simple and effective method for this.
To asses beneﬁt of screening in Italy we developed a cost-
effectiveness Markov model comparing screening vs non screen-
ing scenario. METHODS: We considered a patient cohort
composed of 65 years old men screened for AAA in the Italian
NHS perspective and compared it to a non-screened population.
We collected data both from literature and from a real screening
program that is on-going in San Martino Hospital in Genova.
The following health states were distinguished: no AAA,
unknown small-AAA (3–3.9 cm), followed-up small-AAA (1
year), unknown medium-AAA (4–4.9 cm), followed-up medium-
AAA (6 months), unknown large-AAA (>5 cm), elective repair,
emergency repair, electively repaired AAA, emergency repaired
AAA, rejected large AAA and death. Transition between health
states were simulated using 6-month cycles. Incremental cost per
life year saved was calculated for a 35-year time horizon and
applying a 3% discount rate to both cost and beneﬁts. RESULTS:
Considering an attendance rate of 70%, the individual cost per
invited subject was €104.42. 0.024 additional life years was
gained per patient in the screened cohort, corresponding to an
ICER of €4363/LYS. Univariate and multi-variate sensitivity
analyses were performed for all parameters. The results were not
sensitive to changes in parameters and suggest that screening for
AAA is cost-effective with a probability approaching 100%
based on a willingness-to-pay threshold of €30,000. CONCLU-
SIONS: Similarly to economic evaluations developed in other
countries like UK, Canada, etc, the setting up of a screening
program for AAA can be considered to be cost-effective in the
Italian NHS perspective.
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OBJECTIVES: Recent progress has enabled physicians to meet
the challenge of syncope diagnosis and provide faster and better
guided treatment to the patient. Syncope investigation tradition-
ally included loosely-deﬁned combinations of ECGs, Holter
Monitors, Tilt Tests, EP Studies and Imaging Diagnostics. While
tests were being performed, patients remained at risk of death,
falls and fractures. We wanted to examine the potential cost-
effectiveness of adding an Implantable Loop Recorder to the
traditional clinical pathway. Clinical evidence increasingly dem-
onstrates that ILR-enhanced diagnostics may enable physicians
to achieve more clear diagnoses, at a fraction of the time.
METHODS: We developed a decision-analytic model in
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